Octave Bioscience Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
99
- Latest Deal Type
-
Series D
- (Cancelled)
- Investors
-
15
Octave Bioscience General Information
Description
Developer of a biomarker-based precision neurology platform designed to inform care decisions. The company offers comprehensive biomarker testing and data analytics capabilities, enabling neurologists and patients managing Multiple Sclerosis and Parkinson's disease to gain objective insights that support informed care decisions and improved patient outcomes.
Contact Information
Website
www.octavebio.comCorporate Office
- 1440 O'Brien Drive
- Suite B
- Menlo Park, CA 94025
- United States
Corporate Office
- 1440 O'Brien Drive
- Suite B
- Menlo Park, CA 94025
- United States
Octave Bioscience Timeline
Octave Bioscience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series D) | 21-Feb-2026 | Cancelled | Generating Revenue | |||
| 6. Later Stage VC (Series C) | 22-Mar-2025 | Completed | Generating Revenue | |||
| 5. Grant | 15-Nov-2023 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series B) | 26-Jul-2023 | Completed | Generating Revenue | |||
| 3. Grant | 23-Mar-2022 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 12-Jul-2018 | $19M | $21.5M | Completed | Generating Revenue | |
| 1. Seed Round | 13-Sep-2017 | $2.5M | $2.5M | Completed | Generating Revenue |
Octave Bioscience Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A | ||||||||
| Seed | 2,500,000 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 7.67% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Octave Bioscience Comparisons
Industry
Financing
Details
Octave Bioscience Competitors (45)
One of Octave Bioscience’s 45 competitors is InsightRx, a Venture Capital-Backed company based in San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| InsightRx | Venture Capital-Backed | San Francisco, CA | ||||
| Lightbeam Health Solutions | Venture Capital-Backed | Dallas, TX | ||||
| OmeCare | Formerly VC-backed | San Diego, CA | ||||
| NantHealth | Formerly VC-backed | Lewisville, TX | ||||
| CSI Laboratories | Formerly PE-Backed | Alpharetta, GA |
Octave Bioscience Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Octave Bioscience Patents
Octave Bioscience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250349440-A1 | Biomarker panels for predicting multiple sclerosis disease progression | Pending | 25-Oct-2022 | ||
| WO-2024092055-A1 | Biomarkers for predicting multiple sclerosis disease progression | Inactive | 25-Oct-2022 | ||
| WO-2024081800-A1 | Measuring brain volumes for modeling neurological disease state | Inactive | 12-Oct-2022 | ||
| AU-2021336985-A1 | Biomarkers for predicting multiple sclerosis disease progression | Pending | 04-Sep-2020 | ||
| AU-2021336985-A9 | Biomarkers for predicting multiple sclerosis disease progression | Pending | 04-Sep-2020 | G01N33/6896 |
Octave Bioscience Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Octave Bioscience Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Michael J. Fox Foundation | Limited Partner | |||
| Byers Capital Investment Advisory | Family Office | Minority | ||
| Casdin Capital | Venture Capital | Minority | ||
| Deerfield Management | Venture Capital | Minority | ||
| dRx Capital Novartis | Venture Capital | Minority |
Octave Bioscience FAQs
-
When was Octave Bioscience founded?
Octave Bioscience was founded in 2014.
-
Where is Octave Bioscience headquartered?
Octave Bioscience is headquartered in Menlo Park, CA.
-
What is the size of Octave Bioscience?
Octave Bioscience has 99 total employees.
-
What industry is Octave Bioscience in?
Octave Bioscience’s primary industry is Laboratory Services (Healthcare).
-
Is Octave Bioscience a private or public company?
Octave Bioscience is a Private company.
-
What is Octave Bioscience’s current revenue?
The current revenue for Octave Bioscience is .
-
How much funding has Octave Bioscience raised over time?
Octave Bioscience has raised $129M.
-
Who are Octave Bioscience’s investors?
Michael J. Fox Foundation, Byers Capital Investment Advisory, Casdin Capital, Deerfield Management, and dRx Capital Novartis are 5 of 15 investors who have invested in Octave Bioscience.
-
Who are Octave Bioscience’s competitors?
InsightRx, Lightbeam Health Solutions, OmeCare, NantHealth, and CSI Laboratories are some of the 45 competitors of Octave Bioscience.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
